A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors

Authors

Aaron S Mansfield, Mayo Clinic
Saiama N Waqar, Washington University School of Medicine in St. Louis
et al

Journal

npj Precision Oncology

Publication Date

8-5-2021

Volume

5

Issue

1

First Page

74

Document Type

Open Access Publication

DOI

10.1038/s41698-021-00214-y

Rights and Permissions

Mansfield, A.S., Hong, D.S., Hann, C.L. et al. A phase I/II study of rovalpituzumab tesirine in delta-like 3—expressing advanced solid tumors. npj Precis. Onc. 5, 74 (2021). doi.org/10.1038/s41698-021-00214-y Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Recommended Citation

Mansfield, Aaron S; Waqar, Saiama N; and et al, "A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors." npj Precision Oncology. 5, 1. 74 (2021).
https://digitalcommons.wustl.edu/open_access_pubs/11682